Details of the Drug

General Information of Drug (ID: DMB08GE)

Drug Name
Sulfamethoxazole
Synonyms
sulfamethoxazole; 723-46-6; Gantanol; Sulphamethoxazole; Sulfisomezole; Sulfamethoxazol; Metoxal; Sulfamethylisoxazole; Simsinomin; Radonil; Sinomin; Sulphamethoxazol; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; Sulpha-methoxizole; Sulfamethalazole; Azo-gantanol; Sulphamethylisoxazole; Urobak; Sulfamethoxizole; 3-Sulfanilamido-5-methylisoxazole; Gantanol-DS; 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide; Bactrimel; Gamazole; Sulphisomezole; Sulfametoxazol; Solfametossazolo; Sulfamethoxazolum; Ro 4-2130; SMX; Septran; Sulphamethalazole; Trib; Solfametossazolo [DCIT]; Sulfamethoxazole sodium; MS 53; Sulphamethoxazole BP 98; ALBB-002089; Apo-Sulfamethoxazole; Bactrim (TN); Septra (TN); Septrin (TN); Sulfamethoxazolum [INN-Latin]; Sulfametoxazol [INN-Spanish]; Ro 6-2580/11; Ro-4-2130; Sulfamethoxazole [USAN:INN:JAN]; Sulfamethoxazole (JP15/USP/INN); N1-(5-Methyl-3-isoxazolyl)sulfanilamide; N1-(5-Methylisoxazol-3-yl)sulfanilamide; SULFAMETHOXAZOLE (8064-90-2 (TRIMETHOPRIM/SULFAMETHOXAZOLE); N'-(5-Methyl-3-isoxazole)sulfanilamide; N'-(5-Methyl-3-isoxazolyl)sulfanilamide; N'-(5-Methylisoxazol-3-yl)sulphanilamide; N(sup 1)-(5-Methyl-3-isoxazolyl)sulfanilamide; N(sup 1)-(5-Methyl-3-isoxazolyl)sulphanilamide; N(sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)-(8CI); 3-(p-Aminophenylsulfonamido)-5-methylisoxazole; 3-(para-Aminophenylsulphonamido)-5-methylisoxazole; 3-Sulphanilamido-5-methylisoxazole; 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide; 4-Amino-N-[5-methyl-3-isoxazolyl]benzenesulfonamide; 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide; 5-Methyl-3-sulfanilamidoisoxazole; 5-Methyl-3-sulfanylamidoisoxazole; 5-Methyl-3-sulphanil-amidoisoxazole; Sulphameth oxazole
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1], [2]
Infection of P. falciparum 1F40 Investigative [3]
Therapeutic Class
Antiinfective Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 253.28
Topological Polar Surface Area (xlogp) 0.9
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 57.4-68.0 mg/L [4]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1-4 h [4]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Bioavailability
The bioavailability of drug is 85-90% [4]
Clearance
The renal clearance of drug is 0.22 +/- 0.05 L/h [6]
Elimination
Approximately 84.5% of a single oral dose of sulfamethoxazole is recovered in the urine within 72 hours, of which ~30% is free sulfamethoxazole and the remainder is the N4-acetylated metabolite [7]
Half-life
The concentration or amount of drug in body reduced by one-half in 10 hours [7]
Metabolism
The drug is metabolized via the arylamine N-acetyltransferase (NAT) enzymes, which are responsible for acetylation of sulfamethoxazole at its N4 position [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 394.82001 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.23% [9]
Vd
The volume of distribution (Vd) of drug is 13 L [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.392 mg/mL [5]
Chemical Identifiers
Formula
C10H11N3O3S
IUPAC Name
4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide
Canonical SMILES
CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N
InChI
InChI=1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)
InChIKey
JLKIGFTWXXRPMT-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5329
ChEBI ID
CHEBI:9332
CAS Number
723-46-6
DrugBank ID
DB01015
TTD ID
D0R9OH
VARIDT ID
DR01206
INTEDE ID
DR1511

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Dihydropteroate synthetase (Bact folP) TT4ILYC DHPS_ECOLI Inhibitor [10], [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [11]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [12]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [13]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [14]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [14]
RNA cytidine acetyltransferase (hALP)
Main DME 		DEZV4AP NAT10_HUMAN Substrate [15]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Sulfamethoxazole
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ofloxacin DM0VQN3 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Ofloxacin. Bacterial infection [1A00-1C4Z] [64]
Clarithromycin DM4M1SG Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Clarithromycin. Bacterial infection [1A00-1C4Z] [64]
Sparfloxacin DMB4HCT Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Sparfloxacin. Bacterial infection [1A00-1C4Z] [64]
Gemifloxacin DMHT34O Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Gemifloxacin. Bacterial infection [1A00-1C4Z] [64]
Norfloxacin DMIZ6W2 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Norfloxacin. Bacterial infection [1A00-1C4Z] [64]
Levofloxacin DMS60RB Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Levofloxacin. Bacterial infection [1A00-1C4Z] [64]
⏷ Show the Full List of 6 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Sulfamethoxazole (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Sulfamethoxazole and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [65]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Sulfamethoxazole and Glibenclamide. Acute diabete complication [5A2Y] [66]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Sulfamethoxazole and Insulin-glulisine. Acute diabete complication [5A2Y] [66]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Sulfamethoxazole and Insulin-aspart. Acute diabete complication [5A2Y] [67]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Sulfamethoxazole and Glipizide. Acute diabete complication [5A2Y] [66]
Ivosidenib DM8S6T7 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Ivosidenib. Acute myeloid leukaemia [2A60] [64]
Midostaurin DMI6E0R Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Midostaurin. Acute myeloid leukaemia [2A60] [64]
Idarubicin DMM0XGL Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Idarubicin. Acute myeloid leukaemia [2A60] [64]
Arn-509 DMT81LZ Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Arn-509. Acute myeloid leukaemia [2A60] [64]
Gilteritinib DMWQ4MZ Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Gilteritinib. Acute myeloid leukaemia [2A60] [64]
Oliceridine DM6MDCF Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Oliceridine. Acute pain [MG31] [64]
Bepridil DM0RKS4 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Bepridil. Angina pectoris [BA40] [64]
Dronedarone DMA8FS5 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Dronedarone. Angina pectoris [BA40] [64]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Sulfamethoxazole and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [68]
Cilostazol DMZMSCT Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Cilostazol. Arterial occlusive disease [BD40] [64]
Posaconazole DMUL5EW Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Posaconazole. Aspergillosis [1F20] [64]
Lisdexamfetamine DM6W8V5 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [64]
Desipramine DMT2FDC Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Desipramine. Attention deficit hyperactivity disorder [6A05] [64]
Retigabine DMGNYIH Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Retigabine. Behcet disease [4A62] [64]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Sulfamethoxazole and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [69]
Eribulin DM1DX4Q Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Eribulin. Breast cancer [2C60-2C6Y] [64]
Lapatinib DM3BH1Y Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Lapatinib. Breast cancer [2C60-2C6Y] [64]
Alpelisib DMEXMYK Moderate Increased metabolism of Sulfamethoxazole caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [70]
Bosutinib DMTI8YE Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Bosutinib. Breast cancer [2C60-2C6Y] [64]
PF-04449913 DMSB068 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [64]
Olodaterol DM62B78 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Olodaterol. Chronic obstructive pulmonary disease [CA22] [64]
Anisindione DM2C48U Major Decreased metabolism of Sulfamethoxazole caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [71]
Halothane DM80OZ5 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Halothane. Corneal disease [9A76-9A78] [64]
Sevoflurane DMC9O43 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Sevoflurane. Corneal disease [9A76-9A78] [64]
Probucol DMVZQ2M Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Probucol. Coronary atherosclerosis [BA80] [64]
Mycophenolic acid DMU65NK Moderate Altered absorption of Sulfamethoxazole due to GI flora changes caused by Mycophenolic acid. Crohn disease [DD70] [72]
Pasireotide DMHM7JS Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Pasireotide. Cushing syndrome [5A70] [64]
Osilodrostat DMIJC9X Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Osilodrostat. Cushing syndrome [5A70] [64]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Sulfamethoxazole caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [73]
Sertraline DM0FB1J Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Sertraline. Depression [6A70-6A7Z] [64]
Escitalopram DMFK9HG Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Escitalopram. Depression [6A70-6A7Z] [64]
Clomipramine DMINRKW Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Clomipramine. Depression [6A70-6A7Z] [64]
Doxepin DMPI98T Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Doxepin. Depression [6A70-6A7Z] [64]
Tetrabenazine DMYWQ0O Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [64]
Deutetrabenazine DMUPFLI Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Deutetrabenazine. Dystonic disorder [8A02] [64]
Ingrezza DMVPLNC Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Ingrezza. Dystonic disorder [8A02] [64]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Sulfamethoxazole and Cannabidiol. Epileptic encephalopathy [8A62] [74]
Solifenacin DMG592Q Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Solifenacin. Functional bladder disorder [GC50] [64]
Ketoconazole DMPZI3Q Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Ketoconazole. Fungal infection [1F29-1F2F] [64]
Sunitinib DMCBJSR Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Sunitinib. Gastrointestinal stromal tumour [2B5B] [64]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Sulfamethoxazole and Brentuximab vedotin. Hodgkin lymphoma [2B30] [75]
Saquinavir DMG814N Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [64]
Etravirine DMGV8QU Moderate Decreased metabolism of Sulfamethoxazole caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [76]
Rilpivirine DMJ0QOW Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [64]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Sulfamethoxazole caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [65]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Sulfamethoxazole and Mipomersen. Hyper-lipoproteinaemia [5C80] [77]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Sulfamethoxazole and BMS-201038. Hyper-lipoproteinaemia [5C80] [78]
Givosiran DM5PFIJ Moderate Increased risk of nephrotoxicity by the combination of Sulfamethoxazole and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [65]
Lesinurad DMUR64T Moderate Decreased metabolism of Sulfamethoxazole caused by Lesinurad mediated inhibition of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [79]
Crizotinib DM4F29C Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Crizotinib. Lung cancer [2C25] [64]
Ceritinib DMB920Z Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Ceritinib. Lung cancer [2C25] [64]
PF-06463922 DMKM7EW Moderate Increased metabolism of Sulfamethoxazole caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [65]
Osimertinib DMRJLAT Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Osimertinib. Lung cancer [2C25] [64]
Selpercatinib DMZR15V Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Selpercatinib. Lung cancer [2C25] [64]
Lumefantrine DM29GAD Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Lumefantrine. Malaria [1F40-1F45] [64]
Halofantrine DMOMK1V Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Halofantrine. Malaria [1F40-1F45] [64]
Hydroxychloroquine DMSIVND Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Hydroxychloroquine. Malaria [1F40-1F45] [64]
Primaquine DMWQ16I Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Primaquine. Malaria [1F40-1F45] [64]
Inotuzumab ozogamicin DMAC130 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [64]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Sulfamethoxazole and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [80]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Sulfamethoxazole and Idelalisib. Mature B-cell leukaemia [2A82] [81]
Arsenic trioxide DM61TA4 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Arsenic trioxide. Mature B-cell lymphoma [2A85] [64]
Vemurafenib DM62UG5 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Vemurafenib. Melanoma [2C30] [64]
LGX818 DMNQXV8 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and LGX818. Melanoma [2C30] [64]
Panobinostat DM58WKG Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Panobinostat. Multiple myeloma [2A83] [64]
Siponimod DM2R86O Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Siponimod. Multiple sclerosis [8A40] [64]
Fingolimod DM5JVAN Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Fingolimod. Multiple sclerosis [8A40] [64]
Ozanimod DMT6AM2 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Ozanimod. Multiple sclerosis [8A40] [64]
Romidepsin DMT5GNL Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Romidepsin. Mycosis fungoides [2B01] [64]
Nilotinib DM7HXWT Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Nilotinib. Myeloproliferative neoplasm [2A20] [64]
Dasatinib DMJV2EK Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Dasatinib. Myeloproliferative neoplasm [2A20] [64]
Promethazine DM6I5GR Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Promethazine. Nausea/vomiting [MD90] [64]
Entrectinib DMMPTLH Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Entrectinib. Non-small cell lung cancer [2C25] [64]
Levomethadyl Acetate DM06HG5 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Levomethadyl Acetate. Opioid use disorder [6C43] [64]
Lofexidine DM1WXA6 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Lofexidine. Opioid use disorder [6C43] [64]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Sulfamethoxazole caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [82]
Triclabendazole DMPWGBR Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Triclabendazole. Parasitic worm infestation [1F90] [64]
Pimavanserin DMR7IVC Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Pimavanserin. Parkinsonism [8A00] [64]
Macimorelin DMQYJIR Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Macimorelin. Pituitary gland disorder [5A60-5A61] [64]
Lefamulin DME6G97 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Lefamulin. Pneumonia [CA40] [64]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Sulfamethoxazole caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [83]
Degarelix DM3O8QY Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Degarelix. Prostate cancer [2C82] [64]
ABIRATERONE DM8V75C Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and ABIRATERONE. Prostate cancer [2C82] [64]
Enzalutamide DMGL19D Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Enzalutamide. Prostate cancer [2C82] [64]
Relugolix DMK7IWL Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Relugolix. Prostate cancer [2C82] [64]
Bicalutamide DMZMSPF Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Bicalutamide. Prostate cancer [2C82] [64]
Levomepromazine DMIKFEL Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Levomepromazine. Psychotic disorder [6A20-6A25] [64]
Gatifloxacin DMSL679 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Gatifloxacin. Respiratory infection [CA07-CA4Z] [64]
Quetiapine DM1N62C Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Quetiapine. Schizophrenia [6A20] [64]
Aripiprazole DM3NUMH Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Aripiprazole. Schizophrenia [6A20] [64]
Iloperidone DM6AUFY Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Iloperidone. Schizophrenia [6A20] [64]
Paliperidone DM7NPJS Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Paliperidone. Schizophrenia [6A20] [64]
Amisulpride DMSJVAM Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Amisulpride. Schizophrenia [6A20] [64]
Asenapine DMSQZE2 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Asenapine. Schizophrenia [6A20] [64]
Pimozide DMW83TP Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Pimozide. Schizophrenia [6A20] [64]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Sulfamethoxazole and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [74]
LEE011 DMMX75K Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and LEE011. Solid tumour/cancer [2A00-2F9Z] [64]
Vandetanib DMRICNP Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [64]
Triptorelin DMTK4LS Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [64]
Pitolisant DM8RFNJ Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Pitolisant. Somnolence [MG42] [64]
Telavancin DM58VQX Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [64]
Lenvatinib DMB1IU4 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Lenvatinib. Thyroid cancer [2D10] [64]
Cabozantinib DMIYDT4 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Cabozantinib. Thyroid cancer [2D10] [64]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Sulfamethoxazole and Tolbutamide. Type 2 diabetes mellitus [5A11] [84]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Sulfamethoxazole and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [66]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Sulfamethoxazole and Insulin degludec. Type-1/2 diabete [5A10-5A11] [66]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Sulfamethoxazole and Plazomicin. Urinary tract infection [GC08] [65]
Trimeprazine DMEMV9D Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [64]
Procainamide DMNMXR8 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Procainamide. Ventricular tachyarrhythmia [BC71] [64]
Propafenone DMPIBJK Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Propafenone. Ventricular tachyarrhythmia [BC71] [64]
Flecainide DMSQDLE Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Flecainide. Ventricular tachyarrhythmia [BC71] [64]
Amiodarone DMUTEX3 Minor Increased risk of prolong QT interval by the combination of Sulfamethoxazole and Amiodarone. Ventricular tachyarrhythmia [BC71] [85]
⏷ Show the Full List of 117 DDI Information of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
3 Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
4 Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections. J Chemother. 2017 Dec;29(sup1):10-18. doi: 10.1080/1120009X.2017.1380357.
5 BDDCS applied to over 900 drugs
6 van der Ven AJ, Mantel MA, Vree TB, Koopmans PP, van der Meer JW: Formation and elimination of sulphamethoxazole hydroxylamine after oral administration of sulphamethoxazole. Br J Clin Pharmacol. 1994 Aug;38(2):147-50. doi: 10.1111/j.1365-2125.1994.tb04339.x.
7 FDA Approved Drug Products: Bactrim (sulfamethoxazole/trimethoprim) oral tablets
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10 In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother. 1995 Apr;39(4):948-52.
11 The effect of cimetidine on the formation of sulfamethoxazole hydroxylamine in patients with human immunodeficiency virus. J Clin Pharmacol. 1998 May;38(5):463-6.
12 Reduction of sulfamethoxazole and dapsone hydroxylamines by a microsomal enzyme system purified from pig liver and pig and human liver microsomes. Life Sci. 2005 May 27;77(2):205-19.
13 Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol. 2007 May 1;178(9):5533-42.
14 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
15 Crystallization and preliminary X-ray characterization of arylamine N-acetyltransferase C (BanatC) from Bacillus anthracis. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Oct 1;63(Pt 10):862-4.
16 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
17 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
18 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
19 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
20 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
21 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
22 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
23 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
24 Arylamine N-acetyltransferase in human red blood cells. Biochem Pharmacol. 1992 Sep 25;44(6):1099-104.
25 A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther. 1993 Aug;54(2):134-41.
26 Effect of H2-receptor antagonists on rat liver cytosolic acetyl CoA:arylamine N-acetyltransferase activity. Drug Metab Dispos. 1992 Jan-Feb;20(1):74-8.
27 Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos. 2005 Jul;33(7):969-76.
28 Genetic analysis of bacterial acetyltransferases: identification of amino acids determining the specificities of the aminoglycoside 6'-N-acetyltransferase Ib and IIa proteins. J Bacteriol. 1992 May;174(10):3196-203.
29 NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. Z Gastroenterol. 2008 Mar;46(3):259-65.
30 Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. Eur J Clin Pharmacol. 1999 Jan;54(11):869-76.
31 Aminoglycoside resistance resulting from tight drug binding to an altered aminoglycoside acetyltransferase. Antimicrob Agents Chemother. 2003 May;47(5):1577-83.
32 Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab Lett. 2007 Jan;1(1):3-5.
33 Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension. Clin Pharmacol Ther. 1981 May;29(5):588-93.
34 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
35 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
36 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
37 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
38 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
39 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
40 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
41 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
42 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
43 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
44 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
45 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
46 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
47 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
48 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
49 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
50 Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
51 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
52 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
53 The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
54 The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
55 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
56 Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling. Bioorg Med Chem. 2008 May 15;16(10):5788-94.
57 Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
58 Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7.
59 The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
60 Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995 Aug;39(8):1756-63.
61 A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim an... J Chromatogr A. 2009 Nov 13;1216(46):8110-6.
62 Structures of gramicidins A, B, and C incorporated into sodium dodecyl sulfate micelles. Biochemistry. 2001 Oct 2;40(39):11676-86.
63 Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol. 2004 Jul;11(7):949-57.
64 Canadian Pharmacists Association.
65 Cerner Multum, Inc. "Australian Product Information.".
66 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
67 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
68 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
69 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
70 Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
71 Hermida J, Zarza J, Alberca I, et al. "Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol." Blood 99 (2002): 4237-9. [PMID: 12010835]
72 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
73 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
74 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
75 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
76 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
77 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
78 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
79 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
80 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
81 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
82 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
83 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
84 Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
85 Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908. [PMID: 12885102]